Trial Profile
A Phase I Dose Escalation Study of Vandetanib (ZactimaTM , ZD6474) With Hypofractionated Stereotactic Radiotherapy in Patients With Recurrent Malignant Gliomas.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary)
- Indications Glioma
- Focus Adverse reactions
- 14 Jan 2009 Additional identifier (NCT00822887), endpoints and investigators reported by ClinicalTrials.gov.
- 14 Jan 2009 Additional identifier (NCT00822887), endpoints and investigators reported by ClinicalTrials.gov.
- 15 Aug 2008 New trial record.